The FDA is reviewing Insmed’s application for ARIKAYCE (inhaled liposomal amikacin) and the FDA needs to hear from you now. Please consider writing to the FDA to let them know why it’s so important that we finally have this approved therapy. The review deadline set by the FDA is September 28th. We do not know at this time whether the date will be extended, so please send your letter as soon as possible.
 
Click here for key points to incorporate in your message and contact information for sending your message to the FDA via email or U.S. mail.

If you have any questions, please email [email protected] and someone from NTMir will be happy to assist you.